Clinical trial · Interventional
Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma
Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The main purpose of this protocol is to estimate the percentage of patients with intermediate risk Hodgkin lymphoma who will survive free of disease (Event-free survival) for three years after treatment with multi-agent chemotherapy (Stanford V) and low-dose, tailored-field radiation therapy. The hypothesis being studied is that this treatment will result in more than 80% of patients being alive and free of disease three years after starting treatment.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hodgkin's Lymphoma | Hodgkin Lymphoma | ALIAS | 0.90 |
Interventions
Interventions (10)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adriamycin® | Drug | — | UNRESOLVED |
| Bleomycin | Drug | Bleomycin | ALIAS |
| Cyclophosphamide | Drug | Cyclophosphamide | ALIAS |
| Etoposide | Drug | Etoposide | ALIAS |
| G-CSF | Biological | — | UNRESOLVED |
| Nitrogen Mustard | Drug | — | UNRESOLVED |
| Prednisone | Drug | Prednisone | ALIAS |
| Radiotherapy | Procedure | — | UNRESOLVED |
| Vinblastine | Drug |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- All Participants
- description
- Participants receive 12 weeks of Stanford V chemotherapy which includes Adriamycin®, Vinblastine, Nitrogen Mustard (or Cyclophosphamide), Vincristine, Bleomycin, Etoposide, Prednisone, and G-CSF. After completion of 12 weeks of Stanford V chemotherapy, participants receive radiotherapy.
- interventionNames
- Drug: Adriamycin®
- Drug: Vinblastine
- Drug: Nitrogen Mustard
- Drug: Cyclophosphamide
- Drug: Vincristine
- Drug: Bleomycin
- Drug: Etoposide
- Drug: Prednisone
- Biological: G-CSF
- Procedure: Radiotherapy
Primary outcomes (1)
- measure
- 3-year Event-Free Survival Probability
- timeFrame
- 3 years
- description
- The survival probability for the time interval from treatment start to the time of the first failure (disease recurrence, second malignancy or death) within a 3-year time frame.
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Patient is less than or equal to 21 years of age * Patient has a confirmed diagnosis of previously untreated Hodgkin lymphoma * Has Ann Arbor stage IB, IIIA, or IA/IIA with extranodal extension, multiple nodal involvement (3 or more sites), or bulky mediastinal adenopathy. Exclusion Criteria: * Patients with favorable risk features * Patients with unfavorable risk features * Patients who have received prior therapy for Hodgkin lymphoma.
References
Publications (0)
Data not yet available